IRIS
MUSTO, Pellegrino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.979
AS - Asia 7.455
EU - Europa 5.993
SA - Sud America 3.255
AF - Africa 442
Continente sconosciuto - Info sul continente non disponibili 9
OC - Oceania 8
Totale 28.141
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.609
IT - Italia 2.752
SG - Singapore 2.701
BR - Brasile 2.588
HK - Hong Kong 1.301
CN - Cina 1.232
VN - Vietnam 838
RU - Federazione Russa 723
SE - Svezia 556
FR - Francia 555
DE - Germania 466
GB - Regno Unito 331
BD - Bangladesh 293
AR - Argentina 248
IN - India 232
FI - Finlandia 188
CA - Canada 147
MX - Messico 114
ID - Indonesia 110
IQ - Iraq 109
ZA - Sudafrica 98
EC - Ecuador 96
TR - Turchia 95
CO - Colombia 90
PK - Pakistan 82
CI - Costa d'Avorio 78
VE - Venezuela 67
PL - Polonia 59
SA - Arabia Saudita 59
MA - Marocco 58
UZ - Uzbekistan 58
PY - Paraguay 53
NL - Olanda 49
AT - Austria 48
JP - Giappone 47
UA - Ucraina 47
TN - Tunisia 46
CL - Cile 44
PH - Filippine 41
ES - Italia 38
EG - Egitto 37
PE - Perù 36
IE - Irlanda 35
MY - Malesia 31
KE - Kenya 28
JO - Giordania 27
AZ - Azerbaigian 25
CZ - Repubblica Ceca 22
JM - Giamaica 22
DZ - Algeria 21
CR - Costa Rica 20
KZ - Kazakistan 19
NP - Nepal 19
ET - Etiopia 18
IL - Israele 16
BE - Belgio 15
BO - Bolivia 15
LT - Lituania 14
OM - Oman 14
CH - Svizzera 13
HN - Honduras 13
AE - Emirati Arabi Uniti 12
SN - Senegal 12
UY - Uruguay 12
DO - Repubblica Dominicana 11
KR - Corea 10
LB - Libano 10
AL - Albania 9
PA - Panama 9
RS - Serbia 9
TH - Thailandia 9
TT - Trinidad e Tobago 9
GR - Grecia 8
PS - Palestinian Territory 8
SY - Repubblica araba siriana 8
BG - Bulgaria 7
BH - Bahrain 7
GT - Guatemala 7
KG - Kirghizistan 7
NI - Nicaragua 7
XK - ???statistics.table.value.countryCode.XK??? 7
AO - Angola 6
AU - Australia 6
BY - Bielorussia 6
EE - Estonia 6
GE - Georgia 6
TW - Taiwan 6
HR - Croazia 5
HU - Ungheria 5
LV - Lettonia 5
BA - Bosnia-Erzegovina 4
GY - Guiana 4
MU - Mauritius 4
NG - Nigeria 4
PT - Portogallo 4
AM - Armenia 3
BB - Barbados 3
BN - Brunei Darussalam 3
KH - Cambogia 3
LY - Libia 3
Totale 28.070
Salva come PNG Salva come JPEG
Città #
Singapore 1.515
Ashburn 1.319
Hong Kong 1.273
Milan 1.092
Fairfield 1.073
San Jose 776
New York 553
Nyköping 453
Chandler 395
Woodbridge 394
Houston 368
Rome 350
Lawrence 344
Lauterbourg 340
Seattle 340
Cambridge 337
Beijing 321
Ho Chi Minh City 307
Wilmington 295
Roxbury 284
Des Moines 239
Ann Arbor 218
São Paulo 188
Los Angeles 178
Hanoi 166
Dallas 159
Helsinki 145
Santa Clara 143
San Diego 126
Council Bluffs 119
Falkenstein 116
Paris 114
Bari 109
Columbus 99
Boardman 98
London 89
Munich 87
Figino 83
Abidjan 78
Princeton 77
Turin 70
Chicago 63
Rio de Janeiro 63
Frankfurt am Main 61
Buffalo 60
Nuremberg 57
Jakarta 54
Tashkent 54
Brooklyn 51
Belo Horizonte 48
Matera 48
Atlanta 47
Brasília 47
Johannesburg 47
Moscow 47
Potenza 47
Warsaw 47
Jacksonville 46
Porto Alegre 46
Inglewood 43
Curitiba 41
Campinas 40
Mexico City 40
Baghdad 39
Da Nang 39
Tokyo 38
Guayaquil 37
Denver 35
Dhaka 35
Orem 35
Chennai 34
Dublin 34
Haiphong 34
Montreal 34
Shanghai 34
San Francisco 33
Naples 31
Guangzhou 29
Medellín 29
Salvador 29
Nanjing 28
Quito 28
Toronto 28
Phoenix 27
Ribeirão Preto 27
Amman 26
Jeddah 26
Buenos Aires 25
Salt Lake City 25
Florence 23
Nairobi 23
Lahore 22
Lima 22
The Dalles 22
Turku 22
Casablanca 21
Guarulhos 21
Hounslow 21
Vienna 21
Baku 20
Totale 16.984
Salva come PNG Salva come JPEG
Nome #
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 206
Feasibility of Optical Genome Mapping in Cytogenetic Diagnostics of Hematological Neoplasms: A New Way to Look at DNA 202
Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets 194
Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial 190
Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) 189
Cardiovascular events and intensity of treatment in polycythemia vera. 176
Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis 170
Amyloid in bone marrow smears of patients affected by multiple myeloma 159
Differences among young adults, adults, and elderly chronic myeloid leukemia patients. 155
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma 154
After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia 144
DARA-VD VERSUS DARA-RD AS SALVAGE THERAPY FOR PATIENTS WITH MYELOMA. INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY RETE EMATOLOGICA PUGLIESE 142
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response 139
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis 137
Observational study of chronic myeloid leukemia italian patients who discontinued tyrosine kinase inhibitors in clinical practice 134
Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link? 133
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis 133
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 131
RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia 130
Global methylation patterns in primary plasma cell leukemia 127
Myeloma cells regulate miRNA transfer from fibroblast-derived exosomes by expression of lncRNAs 126
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts 125
Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells 125
FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. 123
Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. 123
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial 122
Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia 122
SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance 121
REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA 120
Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project 120
Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma 118
Epitranscriptomics in normal and malignant hematopoiesis 117
The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells 114
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 112
Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma 112
Analysis of amount, size, protein phenotype and molecular content of circulating extracellular vesicles identifies new biomarkers in multiple myeloma 111
Exploring the Potential of Eltrombopag: Room for More? 110
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency 110
What Is New in the Treatment of Smoldering Multiple Myeloma? 109
Single-Cell Sequencing: Ariadne's Thread in the Maze of Acute Myeloid Leukemia 108
Case report: biallelic DNMT3A mutations in acute myeloid leukemia 105
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity 105
90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma 104
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) 101
Can the new and old drugs exert an immunomodulatory effect in acute myeloid leukemia? 101
null 101
Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study 101
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 100
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma 100
IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis 100
Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients 99
Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia 98
Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why? 96
Hypereosinophilia with a pinch of salt and pepper 96
Optical Genome Mapping as a Tool to Unveil New Molecular Findings in Hematological Patients with Complex Chromosomal Rearrangements 95
IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater? 95
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 95
TNFRSF13B gene mutation in familial acute myeloid leukemia: A new piece in the complex scenario of hereditary predisposition? 95
JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? 95
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial 95
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia 95
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 95
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 95
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: A pooled analysis of two studies 95
Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients 95
Efficacy of Remdesivir and Neutralizing Monoclonal Antibodies in Monotherapy or Combination Therapy in Reducing the Risk of Disease Progression in Elderly or Immunocompromised Hosts Hospitalized for COVID-19: A Single Center Retrospective Study 94
Humoral Immune Response after anti-SARS-CoV-2 Vaccine "Booster" Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) 93
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival 93
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia 92
Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma 91
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 91
Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia 90
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach. 90
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 90
Clonal hematopoiesis in clinical practice: walking a tightrope 89
Immunomodulatory drugs in acute myeloid leukemia treatment 89
Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients 89
CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia 89
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. 88
Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor 88
Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients 87
Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event 87
Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study 87
Gastric normal adjacent mucosa versus healthy and cancer tissues: Distinctive transcriptomic profiles and biological features 87
The Impact of Graft CD3 Cell/Regulatory T Cell Ratio on Acute Graft-versus-Host Disease and Post-Transplantation Outcome: A Prospective Multicenter Study of Patients with Acute Leukemia Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation 87
Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia 86
null 85
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma 85
Concomitant cutaneous T‐cell lymphoma and biclonal B‐cell lymphoproliferative disorder 84
The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy 84
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia 84
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 84
Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice 84
New treatment strategies for elderly myeloma patients 84
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 83
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial 83
Meningeal Involvement in Primary Plasma Cell Leukemia 83
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches 83
The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms 82
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases 82
Totale 10.992
Salva come PNG Salva come JPEG
Categoria #
all - tutte 178.057
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 178.057
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.498 536 283 17 35 20 291 110 85 244 196 287 394
2022/20231.717 404 234 142 66 102 192 111 142 232 18 46 28
2023/20241.196 97 139 78 56 102 460 57 28 2 14 22 141
2024/20255.918 158 25 399 102 152 616 543 425 340 384 882 1.892
2025/202614.665 1.795 632 1.064 1.862 1.274 615 1.175 534 1.560 1.587 512 2.055
2026/2027492 492 0 0 0 0 0 0 0 0 0 0 0
Totale 29.157